Agenus Inc. (AGEN)
NASDAQ: AGEN · Real-Time Price · USD
3.380
-0.120 (-3.43%)
At close: May 13, 2025, 4:00 PM
3.470
+0.090 (2.66%)
Pre-market: May 14, 2025, 8:10 AM EDT
Agenus Revenue
Agenus had revenue of $24.07M in the quarter ending March 31, 2025, a decrease of -14.07%. This brings the company's revenue in the last twelve months to $99.52M, down -38.34% year-over-year. In the year 2024, Agenus had annual revenue of $103.46M, down -33.81%.
Revenue (ttm)
$99.52M
Revenue Growth
-38.34%
P/S Ratio
0.76
Revenue / Employee
$314,949
Employees
316
Market Cap
92.67M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 103.46M | -52.85M | -33.81% |
Dec 31, 2023 | 156.31M | 58.29M | 59.47% |
Dec 31, 2022 | 98.02M | -197.64M | -66.85% |
Dec 31, 2021 | 295.67M | 207.50M | 235.34% |
Dec 31, 2020 | 88.17M | -61.88M | -41.24% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
AGEN News
- 1 day ago - Agenus Inc. (AGEN) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 2 days ago - Agenus Reports Q1 2025 Financial Results and Key Business Updates - Business Wire
- 2 days ago - Renowned GI Oncology Leader Dr. Richard Goldberg Joins Agenus as Chief Development Officer - Business Wire
- 15 days ago - Agenus to Provide Corporate Update and First Quarter 2025 Financial Report - Business Wire
- 15 days ago - Agenus' BOT/BAL Neoadjuvant Pan-Cancer Data from the NEOASIS Study Presented in an Oral Session at AACR - Business Wire
- 18 days ago - Agenus' BOT/BAL Data in Pretreated Liver Cancer Presented at AACR 2025 - Business Wire
- 20 days ago - Agenus Announces Botensilimab and Balstilimab Presentations at ASCO 2025 - Business Wire
- 7 weeks ago - Agenus to Present New BOT/BAL Data in Two Presentations at AACR 2025 - Business Wire